Other Information .
+Added: (c) During the quarter covered by this report, none of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any
+Added: Rule 10b5-1 trading arrangement (as defined in Item 408(a)(1)(i) of Regulation S-K) or any non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K).
Incorporated By
−Removed: Securities Purchase Agreement, dated as of July 13, 2023, by and among Eterna Therapeutics Inc.
−Removed: and the purchasers party thereto.
−Removed: Exhibit 10.1 to Form 8-K filed on July 18, 2023
−Removed: Registration Rights Agreement, dated as of July 13, 2023, by and among Eterna Therapeutics Inc.
−Removed: and the purchasers party thereto.
−Removed: Exhibit 10.4 to Form 8-K filed on July 18, 2023
−Removed: Form of Senior Convertible Note.
−Removed: Exhibit 10.2 to Form 8-K filed on July 18, 2023
−Removed: Form of Common Stock Purchase Warrant.
−Removed: Exhibit 10.3 to Form 8-K filed on July 18, 2023
−Removed: First Amendment to Exclusive License Agreement, dated as of July 12, 2023, by and between Eterna Therapeutics Inc.
−Removed: and Factor Bioscience Limited.
−Removed: Exhibit 10.1 to Form 8-K filed on July 13, 2023
+Added: Inducement Stock Option Award Agreement entered into with Sanjeev Luther
+Added: Exhibit 99.1 to Form S-8 filed on January 16, 2024
+Added: Employment Agreement, dated as of December 19, 2023, by and among Eterna Therapeutics Inc.
+Added: and Sanjeev Luther.
+Added: Exhibit 10.3 to Form 8-K filed on December 20, 2023
+Added: Employment Agreement, effective January 1, 2023, by and among Eterna Therapeutics Inc.
+Added: and Dorothy Clarke.
+Added: Exhibit 10.16 to Form 10-K filed on March 14, 2024
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
19 unchanged sentences
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).
+Added: * Indicates management contract or compensatory plan.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ETERNA THERAPEUTICS INC.
−Removed: November 13, 2023
−Removed: /s/ Matthew Angel
−Removed: Matthew Angel
−Removed: Chief Executive Officer and President
+Added: /s/ Sanjeev Luther
+Added: Sanjeev Luther
+Added: President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 13, 2023
/s/ Sandra Gurrola
Sandra Gurrola
−Removed: Vice President of Finance
+Added: Senior Vice President of Finance
(Principal Financial Officer and Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.